Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ARTV compared with ABOS: revenue, margins and what each company keeps, and the suppliers and customers both name
ARTV
Artiva Biotherapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
ABOS
Acumen Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
ARTV
Artiva Biotherapeutics, Inc.
vs
ABOS
Acumen Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ARTV, solid
ABOS, dashed
Supply-chain overlap
Revenue flow
ARTV: latest quarter is a loss; flow not drawable. ABOS: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ARTV
1
—
GC Cell
unlisted
supplier
Shared
0
No shared counterparties.
Only ABOS
5
MRK
Merck
supplier
HALO
Halozyme
supplier
—
JCR Pharmaceuticals
unlisted
supplier
—
Lonza Sales
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
unlisted
supplier
1 more · ABOS chain
›
ARTV
Artiva Biotherapeutics, Inc.
Change
4.19
▼
−0.98%
· post 4.19
Mkt cap
$204.8M
Revenue
$251,000
Q1 FY24
ABOS
Acumen Pharmaceuticals, Inc.
Change
0.22
▼
−90.48%
· post 0.22
Closed
Oct 30 '26
Mkt cap
$15.2M
Revenue
—
vs
Compare
Closed
Oct 30 '26
ARTV
Artiva Biotherapeutics, Inc.
vs
ABOS
Acumen Pharmaceuticals, Inc.
4.19
▼
−0.98%
post 4.19
Price
0.22
▼
−90.48%
post 0.22
$204.8M
Mkt cap
$15.2M
Q1 FY24
$251,000
Revenue
—
Change
Change
ARTV
4.19
▼
−0.98%
vs
ABOS
0.22
▼
−90.48%
Closed
Oct 30 '26